We're excited to welcome Dr. Hong Wan to BioDuro as Senior Vice President of DMPK. He will lead our global DMPK and bioanalytical functions, further strengthening our integrated drug discovery capabilities.
With over 25 years of drug discovery project experience across leading pharmaceutical organizations, including AstraZeneca, Hengrui Pharmaceuticals. Dr. Wan is a recognized expert in DMPK, bioanalysis, and preclinical drug safety assessment. He has supported the evaluation of numerous preclinical candidates and led studies enabling multiple IND filing, with several programs advancing to approved drugs. He has authored and co-authored over 50 publications in peer-reviewed journals. He is also Editorial Board of ADMET/DMPK; Expert Opinion on Drug Metabolism & Toxicology.
With expertise spanning small molecules, Peptides, ADCs, PROTACs, and other novel modalities, Dr. Wan is expected to further strengthen BioDuro’s DMPK organization by bringing scientific depth, providing customized solution, operational rigor and strong business insight to the team.
Home
